

ALKEM Laboratories

Estimate change

TP change

Rating change



Bloomberg	ALKEM IN
Equity Shares (m)	120
M.Cap.(INRb)/(USDb)	645.9 / 7.1
52-Week Range (INR)	5934 / 4492
1, 6, 12 Rel. Per (%)	-7/-3/4
12M Avg Val (INR M)	839

Financials & Valuations (INR b)

Y/E MARCH	FY26E	FY27E	FY28E
Sales	145.2	160.8	177.2
EBITDA	29.8	32.1	36.1
Adjusted PAT	24.8	21.6	23.8
EBIT Margin (%)	18.0	17.6	18.1
Adj EPS (INR)	207.7	180.8	199.2
EPS Gr. (%)	14.7	-13.0	10.2
BV/Sh. (INR)	1,148.2	1,263.8	1,397.8

Ratios

Net D-E	-0.1	0.0	-0.1
RoE (%)	18.8	15.0	15.0
RoCE (%)	18.3	14.8	14.8
Payout (%)	29.8	36.1	32.8

Valuations

P/E (x)	26.8	29.9	27.2
EV/EBITDA (x)	21.6	20.1	17.6
Div. Yield (%)	0.9	1.0	1.0
FCF Yield (%)	2.9	-1.6	2.3
EV/Sales (x)	4.4	4.0	3.6

Shareholding Pattern (%)

As On	Dec-25	Sep-25	Dec-24
Promoter	51.2	51.2	55.7
DII	21.5	21.9	18.0
FII	10.0	9.5	10.2
Others	17.3	17.4	16.2

FII includes depository receipts

CMP: INR5,400

TP: INR5,525 (+2%)

Neutral

Acquisition of Occlutech to open opportunities in Med-tech segment

Segmental mix, operating leverage drive beat on earnings

- ALKEM is taking significant steps in its Medtech journey through acquiring Occlutech (develops, manufactures, and commercialized medical devices for congenital heart disease, stroke prevention and heart failure).
- ALKEM would be buying up to 55% stake for a consideration of EUR99m (INR10.6b). Revenue/EBITDA/loss of this company in CY25 was EUR49m/EUR2m/EUR6.8m. ALKEM expects to improve EBITDA margins to 23-24% over the next 3-4 years.
- ALKEM Laboratories reported in-line revenue in 3QFY26. EBITDA/PAT came in 17%/20% higher than our estimates, aided by higher growth in export markets, partly supported by currency movement.
- Strong growth was seen in therapies like VMNs, anti-diabetic, respiratory and derma. This was offset to some extent by muted YoY growth in anti-infectives and gastro-intestinal segments.
- New launches, volume traction in base business and steady progress across non-US markets drove overall export growth for the quarter.
- We reduce our earnings estimates by 4%/5% for FY27/FY28, factoring in a) an increase in raw material prices due to the implementation of minimum import price (MIP) by the government of India, and b) ongoing weakness at industry level in certain therapies in DF segment. We value ALKEM at 28x 12M forward earnings to arrive at a TP of INR5,525.
- Increased efforts toward new ventures (med-tech and Enzene), as well as the step-up in the tax rate, are expected to keep growth in check over FY26-28. Maintain Neutral on limited upside from current levels.

Occlutech acquisition to form a Medtech platform for ALKEM to enter developed markets

- Occlutech is a **leading specialist provider of minimally invasive structural heart occlusion devices** with presence across congenital heart disease, stroke prevention and heart failure segments; commercialized in **70+ countries** with manufacturing facilities in **Germany and Turkey**.
- Its portfolio comprises **10+ product lines** across three therapeutic areas with **200,000+ devices sold** since inception.
- It has delivered ~17% sales CAGR over CY22-24 to EUR43m; estimated to reach EUR49m (~INR4.9b) in CY25, implying ~16.5% CAGR over CY22-25. Over the next five years, ALKEM intends to scale up revenue to INR10b+ and expand EBITDA margin from ~5% currently to ~20-25%.
- This implies EV/EBITDA of ~15x/~7x on CY28E/CY30E EBITDA. The acquisition is 3.6x CY25 sales.
- ALKEM would leverage Occlutech as a global med-tech entry platform across Japan, the US and Europe.

Tushar Manudhane - Research Analyst (Tushar.Manudhane@MotilalOswal.com)

Eshita Jain - Research Analyst (Eshita.Jain@MotilalOswal.com) | **Vipul Mehta** (vipul.mehta@motilaloswal.com)

Investors are advised to refer through important disclosures made at the last page of the Research Report.

Motilal Oswal research is available on www.motilaloswal.com/Institutional-Equities, Bloomberg, Thomson Reuters, Factset and S&P Capital.

- **Our take:** For ALKEM, acquiring an R&D-focused company with presence in developed markets is a good strategy to scale up its med-tech business. The profitability of Occlutech has yet to improve despite being present in this space for 15+ years. With ALKEM also in the process of building its positioning in this space, this would be the key monitorable. The valuation is decent if the performance happens as per guidance.

EBITDA/PAT better than expected

- 3Q revenue grew 10.7% YoY to INR37.4b (our est.: INR36.7b).
- Gross margin expanded 160bp YoY to 66%.
- EBITDA margin was steady YoY at 22.2% (our est.: 19.3%) as higher gross margin was offset by high other expenses/employee cost (up 140bp/80bp YoY as % of sales). R&D expense was stable YoY as % of sales.
- EBITDA grew 9% YoY to INR8.3b (our est. of INR7.1b).
- Adj. PAT grew 8.7% YoY to INR6.8b (our est.: INR5.8b).
- For 9MFY26, revenue/EBITDA/PAT grew 13%/17%/13% YoY.

International growth much higher than DF segment

- DF business grew 5.5% YoY to INR25b (67.2% of sales).
- International business grew 27% YoY to INR12.1b.
- US sales increased by 19% YoY to INR7.7b (20.3% of Sales).
- Other international sales rose 42% YoY to INR4.6b (12.5% of sales).

Highlights from the management commentary

- ALKEM had taken steps to change the distribution set-up in DF, leading to high base last year. Adj for the same, YoY growth would be double digits in 3Q.
- ALKEM expects Enzene and medtech to have EBITDA margin of 25% in 4-5 years.
- In addition to acquisition, ALKEM would invest INR1b-INR2b in R&D at Occlutech over next 1-2 years. Current GM of Occlutech is about 73%.
- There is a debt of INR4b-INR5b on the balance sheet of Occlutech. This can be re-financed using corporate guarantee of ALKEM. In CY25, Occlutech reported revenue of EUR49m, EBITDA of EUR2m, and a loss of EUR6.8m.


About Occlutech

- Occlutech is a leading specialist provider of minimally invasive cardiac devices. Occlutech has developed, produced, and commercialized first-class, minimally invasive, cardiac implants for congenital heart disease, stroke prevention, and heart failure. The devices are sold to hospitals and clinics in over 70 countries. It has manufacturing facilities in Germany and Turkey.
- Occlutech has 10+ product lines in three therapeutic areas. Occlutech has sold 2L+ devices till date since inception.

Financial snapshot: 16-17% sales CAGR over CY22-25E

- Occlutech has delivered 17% sales CAGR over CY22-24 to EUR43m. Considering estimated sales of EUR49m (INR4.9b) in CY25, the sales CAGR over CY22-25 is expected to be 16.5%. There was a net loss of EUR20m in CY24.

Exhibit 1: ALKEM guides for INR6b in revenue in CY26; up 23% YoY




- The loss is expected to reduce to EUR6.8m in CY25. ALKEM has guided for 23% YoY growth in CY26 to reach INR6b in revenue from this entity.
- With growth potential of 14-15% CAGR over the next five years, ALKEM intends to scale up this business to INR10b+.
- From current 5% EBITDA margin, ALKEM intends to scale up EBITDA margin to 20-25% over the next five years.
- **Assuming above performance, revenue/EBITDA are projected to be INR8b/INR1.2b in CY28 and INR10.5b/INR2.6b in CY30. EV/EBITDA would be 18x/8x on CY28/CY30.**

Occluders – a part of structural heart devices


- Occluders form a part of structural heart devices. The market size of occluders is about USD2b (CY24) and is expected to witness CAGR of 4% over FY24-29. The overall structural heart devices market is about USD11b and is expected to grow at compounded rate of 7.8% over FY24-29 to reach USD16b.
- Structural heart disease (SHD) is a problem involving tissues or valves of the heart. All SHDs involve a defect or disorder in the structure of the heart tissue or valves or its functioning. Common symptoms of SHD involve strokes, shortness of breath, high blood pressure, leg cramps, and kidney dysfunction.

Exhibit 2: SHD market expected to witness 7.8% CAGR over CY24-29




- Occluders EU market size is about USD745. The ROW markets is about USD1.8b in CY24. Occluder technology is evolving and includes advanced biodegradable occluders, hybrid occlusion tools, and precision delivery systems for improved the safety and efficacy of occluder devices, providing patients with more treatment options for congenital heart defects.
- Biodegradable occluders are still under clinical evaluation and not yet commercially available and hybrid occlusion tools (which combine multiple functionalities to address various heart defects simultaneously) are not a widely adopted or clearly defined product category in current practice.

Exhibit 1: SHD market by product



TAVI: Transcatheter aortic valve implantation (TAVI), Left atral appendage (LAA), Source: Industry

Exhibit 2: SHD market by geography



Source: Industry

- SHD treatment has witnessed a structural shift from open-heart surgery toward minimally invasive transcatheter interventions, driven by a) aging population, b) rising atrial fibrillation (AF) incidence, c) increasing diagnosis of congenital heart defects, d) rowing adoption of cath-lab based procedure
- **Global companies in the occluder space are Abbott and Lifetech Scientific. Indian companies in this space are SMT and Merill Lifescience. Broadly, it remains an oligopoly market.**

Occlutech – third-largest company in this space

- Notably, Occlutech is the third-largest company in occluder segment. About 85% of revenue is from Western Europe and US market.
- PFO (patent foramen Ovale) is yet to be approved by USFDA. Having said this, Occlutech PFO has 99% procedural success rate and 95% efficient closure rate after six months. Most of R&D spend for this product is largely done.
- USFDA approved Occlutech Atrial Septal Defect (ASD) Occluder and the associated Pistol Pusher delivery system in Dec'23, for treating patients with ostium secundum-type ASD. This minimally invasive, nitinol-based device enables permanent, non-surgical closure of holes in the heart.
- Occlutech partnered with B. Braun Interventional Systems Inc. to commercialize the device in the US following approval. The breakthrough designation was granted by FDA to the Atrial Flow Regulator (AFR) for pulmonary arterial hypertension (PAH). The ASD closure US market size was USD40m at the time of approval for Occlutech. Occlutech has gained 5% market share in 1.5 years time frame.

Plan of action by Alkem

- In addition to the amount paid for acquisition, ALKEM would be investing INR1b- INR2b to fund R&D program.
- Occlutech would be utilized as a platform for medtech offerings in markets like Japan, the US, and Europe in the cardiovascular segment.
- Considering this business has strong gross margin of 73%, ALKEM would be building operating leverage through enhancing offerings and increasing reach.

Quarterly Perf. (Consolidated)

Y/E March	FY25				FY26				FY25	FY26E	FY26E	Var
	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4QE			3QE	%
Net Revenues	30,318	34,147	33,743	31,438	33,711	40,010	37,368	34,116	1,29,645	1,45,205	36,750	1.7
YoY Change (%)	2.2	-0.7	1.5	7.1	11.2	17.2	10.7	8.5	2.3	12.0	8.9	
Total Expenditure	24,232	26,618	26,149	27,525	26,321	30,802	29,088	29,169	1,04,524	1,15,381	29,658	
EBITDA	6,086	7,528	7,594	3,913	7,391	9,208	8,280	4,947	25,121	29,825	7,093	16.7
YoY Change (%)	56.4	0.8	7.3	-2.7	21.4	22.3	9.0	26.4	11.9	18.7	-6.6	
Margins (%)	20.1	22.0	22.5	12.4	21.9	23.0	22.2	14.5	19.4	20.5	19.3	
Depreciation	805	789	853	1,125	877	936	950	924	3,572	3,687	955	
EBIT	5,282	6,739	6,741	2,788	6,514	8,272	7,330	4,022	21,550	26,137	6,138	
YoY Change (%)	66.7	0.2	5.7	-12.5	23.3	22.7	8.7	44.3	57.4	34.3	-8.9	
Margins (%)	17.4	19.7	20.0	8.9	19.3	20.7	19.6	11.8	16.6	18.0	16.7	
Interest	291	281	360	284	298	350	421	320	1,217	1,389	310	
EBT	5,795	7,247	7,234	3,629	7,093	8,858	7,859	4,627	23,904	28,436	6,783	
Margins (%)	19.1	21.2	21.4	11.5	21.0	22.1	21.0	13.6	18.4	19.6	18.5	
Other Income	1,203	1,345	930	1,460	1,365	1,037	1,431	1,050	4,937	4,883	1,150	
PBT before EO Exp	6,194	7,803	7,311	3,963	7,581	8,958	8,340	4,752	25,270	29,631	6,978	19.5
EO Exp/(Inc)	0	0	0	0	-129	0	528	0	0	399	0	
PBT after EO Exp	6,194	7,803	7,311	3,963	7,710	8,958	7,812	4,752	25,270	29,232	6,978	
Tax	691	783	903	733	1,027	1,162	1,277	713	3,110	4,179	1,012	
Rate (%)	11.2	10.0	12.3	18.5	13.3	13.0	16.3	15.0	12.3	14.1	14.5	
PAT (pre-Minority Interest)	5,502	7,020	6,408	3,230	6,683	7,796	6,535	4,040	22,160	25,054	5,966	
Minority Interest	51	133	150	172	41	145	175	195	505	556	190	
Reported PAT	5,452	6,886	6,258	3,059	6,643	7,651	6,360	3,845	21,655	24,498	5,776	10.1
Adj Net Profit	5,452	6,886	6,258	3,059	6,531	7,651	6,802	3,845	21,655	24,828	5,776	20.4
YoY Change (%)	90.1	2.0	-2.6	0.6	19.8	11.1	8.7	25.7	13.5	14.7	-7.7	

Key performance Indicators (Consolidated)

Y/E March	FY25				FY26				FY25	FY26E	FY26
INRm	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4QE			3QE
India formulations	20,223	24,610	23,649	21,355	22,650	27,660	24,959	23,277	89,837	98,546	25,541
YoY Change (%)	6.4	5.7	5.9	8.3	12.0	12.4	5.5	9.0	6.5	9.7	8.0
US generics	6,416	5,744	6,340	6,086	6,982	7,649	7,533	6,812	24,586	29,499	7,226
YoY Change (%)	(7.7)	(25.2)	(7.3)	(2.5)	8.8	33.2	18.8	11.9	(11.3)	20.0	14.0
International (Ex-US)	3,261	3,210	3,265	3,661	3,556	4,241	4,624	4,027	13,397	16,448	3,983
YoY Change (%)	2.2	12.0	(4.0)	28.2	9.0	32.1	41.6	10.0	8.8	22.8	22.0
Cost Break-up											
RM Cost (% of Sales)	35.5	35.3	35.7	40.7	34.7	35.0	34.1	39.0	36.7	35.6	34.0
Staff Cost (% of Sales)	19.9	17.9	18.5	19.6	20.6	17.8	19.3	19.4	18.9	19.2	19.2
R&D Expenses (% of Sales)	4.1	4.3	3.9	5.0	3.5	3.3	3.7	4.1	4.3	3.6	3.7
Other Cost (% of Sales)	20.4	20.5	19.4	22.2	19.3	21.0	20.8	23.5	20.6	21.1	23.8
Gross Margins (%)	64.5	64.7	64.3	59.3	65.3	65.0	65.9	61.0	63.3	64.4	66.0
EBITDA Margins (%)	20.1	22.0	22.5	12.4	21.9	23.0	22.2	14.0	19.4	20.4	19.3
EBIT Margins (%)	17.4	19.7	20.0	8.9	19.3	20.7	19.6	11.3	16.6	17.5	16.7


E: MOFSL Estimates




Management call highlights

- Currently, Occlutech has 150+ shareholders, with 32% being held by the founder. Current management/promoters would work with ALKEM to grow the business over the next 3-4 years at least.
- ALKEM is conservatively building 14% revenue CAGR in the Occlutech business without any new product and without addition to the portfolio.
- With MIP on Pen-G prices, there can be an impact of INR800m-INR1b for ALKEM. Having said this, ALKEM is working on mitigating the risk partly through higher trade generics segment. Typically, ALKEM has 4-5 months of inventory, which can provide some relief before MIP starts impacting profitability of ALKEM.
- ALKEM is bullish on DF segment and is on track to deliver its full-year guidance.


Key exhibits

Exhibit 3: DF revenue grew 5.5% YoY in 3QFY26


Source: MOFSL, Company

Exhibit 4: US sales grew 19% YoY in 3QFY26


Source: MOFSL, Company

Exhibit 5: Cumulative US ANDA filings


Source: MOFSL, Company

Exhibit 6: Robust ANDA pipeline

US Filings	# Nos.
Total ANDAs filed	188
NDA	2

Source: MOFSL, Company

Core pharma traction intact; Medtech entry enhances growth visibility DF: Efforts underway to increase chronic share to aid sustainable growth

- After strong double-digit growth in the prior two quarters, DF growth moderated to 5.5% YoY in 3QFY26, largely due to high base from distribution adjustments in 3QFY25, while underlying billing growth remained healthy.
- Therapy-wise, ALKEM outperformed IPM in six key areas, VMN (2.0x IPM growth), Derma (1.8x IPM growth), Pain (1.4x IPM growth), AI (1.4x IPM growth), Respiratory (1.2x IPM growth), and Anti-Diabetic (1.2x IPM growth).
- A decline in Xone and subdued performance in Pan-D, Taxim-O and A to Z Ns dragged down overall growth below industry levels despite healthy growth in Uprise-D3, Clavam, and Pan in Dec'25.
- For 3QFY26, moderate growth in Anti-infective and Gastro, along with softness in Pain and Neuro in select months, was partly offset by consistent outperformance in VMN and Anti diabetic therapies.
- The company remains focused on sustaining growth above industry levels in the DF segment, with continued strengthening of its chronic portfolio; we estimate ALKEM to deliver ~10% sales CAGR in DF, scaling to ~INR120b over FY25-28.

Healthy international execution across US and Ex-US markets

- International business delivered strong growth in 9MFY26, led by robust traction in both US and Ex-US markets; US continues to be the key contributor to international revenue.
- Ex US markets (+27.6% YoY) outpaced the US (+19.8% YoY) in 9MFY26.
- In non-US markets, growth was broad-based across key geographies, with management highlighting significant headroom in emerging markets, including APAC and EMEA, where penetration remains low.
- In the US, growth was supported by new launches and volume expansion.
- ALKEM filed four ANDAs, one BLA and received 13 ANDA approvals in 9MFY26.
- Overall, we expect ALKEM to deliver 11% sales CAGR in international markets to INR51.7b over FY25-28.


Occlutech platform acquisition; cardio focus to scale over medium term

- Alkem MedTech has announced a binding offer to acquire up to 55% stake in Occlutech Holding AG, Switzerland, for EUR99.4m or ~INR10.7b, marking its entry into advanced cardiovascular devices globally.
- Occlutech reported CY25 revenue of EUR49.4m, delivering 15.7% CAGR over the past three years; the company is EBITDA positive in CY26, with margin expected at ~10% by FY27 and ~23-24% over the next three years.
- ~85% of Occlutech's revenue is derived from Western Europe and the US; it holds ~23% market share in Europe and has achieved ~5% share in the US within 1.5 years of entry, reflecting strong positioning in high entry barrier markets.
- The company's portfolio is focused on minimally invasive structural heart implants for atrial septal defect closure, heart failure and stroke prevention; it ranks third globally and second in Europe in this niche segment.
- The Left Atrial Appendage occluder addresses a ~USD1.4b global market currently dominated by two global players; expected approval and commercialization can materially scale revenues over the medium term.
- Further, management also highlighted denosumab biosimilars, including Xgeva and Prolia, in the pharma pipeline, with US entry expected by CY26 end and Europe launch in the coming months.

Reiterate Neutral


- We reduce our earnings estimates by 4%/5% for FY27/FY28, factoring in a) increase in raw material prices due to the implementation of MIP by the government of India, and b) ongoing weakness at industry level in certain therapies in DF segment. We value ALKEM at 28x 12M forward earnings to arrive at a TP of INR5,525.
- Increased efforts towards new ventures (med-tech and Enzene), as well as the step-up in the tax rate, are expected to keep growth in check over FY26-28. Maintain Neutral on limited upside from current levels.

Exhibit 7: P/E chart



Source: MOFSL, Company, Bloomberg


Exhibit 8: EV/EBITDA chart



Source: MOFSL, Company, Bloomberg


Story in charts

Exhibit 9: Total sales grew 10.7% YoY in 3QFY26




Source: Company, MOFSL

Exhibit 10: Gross margin up 160bp YoY in 3QFY26




Source: Company, MOFSL

Exhibit 11: EBITDA margin down 3bp YoY in 3QFY26




Source: Company, MOFSL

Exhibit 12: EPS grew 8.8% YoY to INR57 in 3QFY26




Source: Company, MOFSL

Exhibit 13: Expect 9.5% sales CAGR in the US over FY25-28




Source: Company, MOFSL

Exhibit 14: EBITDA margin to expand ~100bp over FY25-28




Source: Company, MOFSL

Exhibit 15: Expect revenue CAGR of 11% over FY25-28




Source: Company, MOFSL

Exhibit 16: Expect India sales CAGR of 10% over FY25-28




Source: Company, MOFSL

Exhibit 17: Return ratios expected to moderate ahead



Source: Company, MOFSL

Exhibit 18: Expect earnings to have 3% CAGR over FY25-28



Source: Company, MOFSL

Financials and Valuations

Consolidated - Income Statement

	INRm						
Y/E March	FY22	FY23	FY24	FY25	FY26E	FY27E	FY28E
Total Income from Operations	1,06,342	1,15,993	1,26,676	1,29,645	1,45,205	1,60,834	1,77,229
Change (%)	20.2	9.1	9.2	2.3	12.0	10.8	10.2
Total Expenditure	85,813	99,198	1,04,221	1,04,524	1,15,381	1,28,774	1,41,164
EBITDA	20,529	16,795	22,455	25,121	29,825	32,061	36,065
Margin (%)	19.3	14.5	17.7	19.4	20.5	19.9	20.3
Depreciation	3,040	3,104	2,993	3,572	3,687	3,809	4,064
EBIT	17,490	13,690	19,462	21,550	26,137	28,252	32,001
Int. and Finance Charges	524	1,074	1,124	1,217	1,389	1,064	998
Other Income	1,627	2,161	3,108	4,937	4,883	5,837	4,556
PBT bef. EO Exp.	18,592	14,778	21,446	25,270	29,631	33,024	35,560
EO Items	-150	-1,730	-1,215	0	-399	0	0
PBT after EO Exp.	18,443	13,048	20,231	25,270	29,232	33,024	35,560
Current Tax	1,640	2,980	2,117	3,110	4,179	10,568	10,846
Deferred Tax	0	0	0	0	0	0	0
Tax Rate (%)	8.9	22.8	10.5	12.3	14.3	32.0	30.5
Less: Minority Interest	300	226	157	505	556	840	900
Reported PAT	16,503	9,842	17,958	21,655	24,498	21,616	23,814
Adjusted PAT	16,516	12,678	19,091	21,655	24,828	21,616	23,814
Change (%)	2.6	-23.2	50.6	13.4	14.7	-13.0	10.2
Margin (%)	15.5	10.9	15.1	16.7	17.1	13.4	13.4

Consolidated - Balance Sheet

	INRm						
Y/E March	FY22	FY23	FY24	FY25	FY26E	FY27E	FY28E
Equity Share Capital	239	239	239	239	239	239	239
Total Reserves	86,140	90,214	1,02,882	1,19,610	1,36,311	1,50,098	1,66,052
Net Worth	86,379	90,453	1,03,121	1,19,849	1,36,550	1,50,337	1,66,291
Minority Interest	2,094	3,897	4,023	4,488	4,488	4,488	4,488
Deferred Tax Liabilities	0	0	0	0	0	0	0
Total Loans	26,466	13,775	14,032	13,302	13,302	13,302	13,302
Capital Employed	1,14,939	1,08,125	1,21,176	1,37,638	1,54,340	1,68,127	1,84,080
Gross Block	35,948	36,835	43,260	46,607	52,742	66,771	78,378
Less: Accum. Deprn.	13,077	16,181	19,174	22,745	26,433	30,242	34,306
Net Fixed Assets	22,871	20,654	24,086	23,862	26,310	36,529	44,073
Goodwill on Consolidation	6,146	4,796	4,642	4,662	4,662	4,662	4,662
Capital WIP	3,395	3,103	1,586	5,481	2,847	12,320	4,215
Total Investments	3,710	6,218	4,838	18,455	18,455	18,455	18,455
Curr. Assets, Loans&Adv.	91,477	89,770	1,05,449	1,07,070	1,32,962	1,32,084	1,53,094
Inventory	30,055	26,075	26,612	29,224	32,876	37,044	40,609
Account Receivables	18,846	21,322	22,528	24,663	28,503	32,608	35,931
Cash and Bank Balance	25,786	25,786	15,694	15,631	29,731	15,845	25,219
Loans and Advances	16,790	16,587	40,616	37,552	41,853	46,586	51,335
Curr. Liability & Prov.	25,753	29,442	34,572	39,273	48,278	53,306	57,800
Account Payables	11,734	11,650	17,481	18,394	20,547	22,579	24,752
Other Current Liabilities	7,955	10,370	12,824	15,906	17,727	19,732	21,744
Provisions	6,064	7,421	4,267	4,973	10,003	10,994	11,305
Net Current Assets	65,725	60,329	70,877	67,797	84,684	78,778	95,294
Deferred Tax assets	13,093	13,025	15,148	17,383	17,383	17,383	17,383
Appl. of Funds	1,14,939	1,08,125	1,21,177	1,37,638	1,54,340	1,68,127	1,84,080

Financials and Valuations

Ratios

Y/E March	FY22	FY23	FY24	FY25	FY26E	FY27E	FY28E
Basic (INR)							
EPS	138.1	106.0	159.7	181.1	207.7	180.5	198.6
Cash EPS	163.6	132.0	184.7	211.0	232.6	212.4	232.6
BV/Share	723	757	863	1,002	1,142	1,258	1,391
DPS	59.0	50.0	40.0	45.0	50.0	55.0	55.0
Payout (%)	50.7	72.0	31.6	29.4	29.8	36.1	32.8
Valuation (x)							
P/E	39.1	50.9	33.8	29.8	26.0	29.9	27.2
Cash P/E	33.0	40.9	29.2	25.6	22.66	25.4	23.2
P/BV	7.5	7.1	6.3	5.4	4.7	4.3	3.9
EV/Sales	6.1	5.5	5.1	5.0	4.4	4.0	3.6
EV/EBITDA	31.5	37.7	28.7	25.6	21.1	20.1	17.6
Dividend Yield (%)	1.1	0.9	0.7	0.8	0.9	1.0	1.0
FCF per share	65.5	121.5	147.3	148.6	152.6	-83.4	122.2
Return Ratios (%)							
RoE	20.6	14.3	19.7	19.4	18.8	15.0	15.0
RoCE	17.1	11.3	18.3	18.6	18.3	14.8	14.8
RoIC	21.6	13.6	20.3	19.2	21.6	17.1	17.3
Working Capital Ratios							
Fixed Asset Turnover (x)	3.0	3.1	2.9	2.8	2.7	2.4	2.3
Asset Turnover (x)	0.9	1.1	1.0	0.9	0.9	1.0	1.0
Inventory (Days)	103	82	77	82	83	84	84
Debtor (Days)	65	67	65	69	72	74	74
Creditor (Days)	40	37	50	52	52	51	51
Working Cap. Turnover (Days)	137	109	159	147	139	143	144
Leverage Ratio (x)							
Current Ratio	3.6	3.0	3.1	2.7	2.8	2.5	2.6
Interest Cover Ratio	33.4	12.8	17.3	17.7	18.3	26.5	32.1
Debt/Equity	0.0	-0.1	0.0	0.0	-0.1	0.0	-0.1

Consolidated - Cash Flow Statement

Y/E March	FY22	FY23	FY24	FY25	FY26E	FY27E	FY28E
OP/(Loss) before Tax	18,443	13,048	20,231	25,270	28,919	32,970	35,462
Depreciation	3,040	3,104	2,993	3,572	3,687	3,809	4,064
Interest & Finance Charges	-703	1,074	1,124	-3,720	-3,494	-4,718	-3,461
Direct Taxes Paid	-3,969	-2,734	-4,069	-3,110	-4,179	-10,550	-10,816
(Inc)/Dec in WC	-5,450	3,268	-516	3,017	-3,186	-7,979	-7,142
CF from Operations	11,361	17,759	19,763	25,028	21,748	13,531	18,107
CF from Operating incl EO	11,110	16,825	19,482	25,028	21,748	13,531	18,107
(Inc)/Dec in FA	-3,280	-2,297	-1,868	-7,262	-3,502	-23,502	-3,502
Free Cash Flow	7,830	14,528	17,614	17,767	18,246	-9,971	14,605
(Pur)/Sale of Investments	-12,051	1,955	-10,612	-13,617	0	0	0
Others	980	1,471	2,395	4,937	4,883	5,782	4,459
CF from Investments	-14,351	1,128	-10,085	-15,942	1,381	-17,720	957
Inc/(Dec) in Debt	8,628	-11,408	-5,132	-730	0	0	0
Interest Paid	-401	-905	-913	-1,217	-1,389	-1,064	-998
Dividend Paid	-4,219	-5,295	-5,405	-6,376	-7,084	-7,793	-7,793
CF from Fin. Activity	3,796	-16,388	-19,489	-9,149	-9,029	-9,697	-9,690
Inc/Dec of Cash	555	1,565	-10,093	-62	14,099	-13,885	9,373
Opening Balance	1,705	2,297	3,862	-6,231	-6,293	7,807	-6,079
Closing Cash and Cash Eq.	2,297	3,862	-6,231	-6,293	7,807	-6,079	3,295
Bank Balances	23,489	21,924	21,924	21,924	21,924	21,924	21,924
Total Cash and Cash Eq.	25,786	25,786	15,694	15,631	29,731	15,845	25,219

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

NOTES

Explanation of Investment Rating	
Investment Rating	Expected return (over 12-month)
BUY	>=15%
SELL	< - 10%
NEUTRAL	< - 10 % to 15%
UNDER REVIEW	Rating may undergo a change
NOT RATED	We have forward looking estimates for the stock but we refrain from assigning recommendation

*In case the recommendation given by the Research Analyst is inconsistent with the investment rating legend for a continuous period of 30 days, the Research Analyst shall be within following 30 days take appropriate measures to make the recommendation consistent with the investment rating legend.

Disclosures

The following Disclosures are being made in compliance with the SEBI Research Analyst Regulations 2014 (herein after referred to as the Regulations).

Motilal Oswal Financial Services Ltd. (MOFSL) is a SEBI Registered Research Analyst having registration no. INH000000412. MOFSL, the Research Entity (RE) as defined in the Regulations, is engaged in the business of providing Stock broking services, Depository participant services & distribution of various financial products. MOFSL is a listed public company, the details in respect of which are available on www.motilaloswal.com. MOFSL (erstwhile Motilal Oswal Securities Limited - MOSL) is registered with the Securities & Exchange Board of India (SEBI) and is a registered Trading Member with National Stock Exchange of India Ltd. (NSE) and Bombay Stock Exchange Limited (BSE), Multi Commodity Exchange of India Limited (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) for its stock broking activities & is Depository participant with Central Depository Services Limited (CDSL) National Securities Depository Limited (NSDL), NERL, COMRIS and CCRL and is member of Association of Mutual Funds of India (AMFI) for distribution of financial products and Insurance Regulatory & Development Authority of India (IRDA) as Corporate Agent for insurance products. Details of associate entities of Motilal Oswal Financial Services Limited are available on the website at <http://online.reports.motilaloswal.com/Dormant/documents/List%20of%20Associate%20companies.pdf>

MOFSL and its associate company(ies), their directors and Research Analyst and their relatives may; (a) from time to time, have a long or short position in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein. (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.

MOFSL and / or its affiliates do and seek to do business including investment banking with companies covered in its research reports. As a result, the recipients of this report should be aware that MOFSL may have a potential conflict of interest that may affect the objectivity of this report. Compensation of Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions. Details of pending Enquiry Proceedings of Motilal Oswal Financial Services Limited are available on the website at <https://galaxy.motilaloswal.com/ResearchAnalyst/PublishViewLitigation.aspx>

A graph of daily closing prices of securities is available at www.nseindia.com, www.bseindia.com. Research Analyst views on Subject Company may vary based on Fundamental research and Technical Research. Proprietary trading desk of MOFSL or its associates maintains arm's length distance with Research Team as all the activities are segregated from MOFSL research activity and therefore it can have an independent view with regards to Subject Company for which Research Team have expressed their views.

Regional Disclosures (outside India)

This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL & its group companies to registration or licensing requirements within such jurisdictions.

For Hong Kong:

This report is distributed in Hong Kong by Motilal Oswal capital Markets (Hong Kong) Private Limited, a licensed corporation (CE AYY-301) licensed and regulated by the Hong Kong Securities and Futures Commission (SFC) pursuant to the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) "SFO". As per SEBI (Research Analyst Regulations) 2014 Motilal Oswal Securities (SEBI Reg. No. INH000000412) has an agreement with Motilal Oswal capital Markets (Hong Kong) Private Limited for distribution of research report in Hong Kong. This report is intended for distribution only to "Professional Investors" as defined in Part I of Schedule 1 to SFO. Any investment or investment activity to which this document relates is only available to professional investor and will be engaged only with professional investors." Nothing here is an offer or solicitation of these securities, products and services in any jurisdiction where their offer or sale is not qualified or exempt from registration. The Indian Analyst(s) who compile this report is/are not located in Hong Kong & are not conducting Research Analysis in Hong Kong.

For U.S.

Motilal Oswal Financial Services Limited (MOFSL) is not a registered broker - dealer under the U.S. Securities Exchange Act of 1934, as amended (the "1934 act") and under applicable state laws in the United States. In addition MOFSL is not a registered investment adviser under the U.S. Investment Advisers Act of 1940, as amended (the "Advisers Act" and together with the 1934 Act, the "Acts"), and under applicable state laws in the United States. Accordingly, in the absence of specific exemption under the Acts, any brokerage and investment services provided by MOFSL, including the products and services described herein are not available to or intended for U.S. persons. This report is intended for distribution only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the Exchange Act and interpretations thereof by SEC (henceforth referred to as "major institutional investors"). This document must not be acted on or relied on by persons who are not major institutional investors. Any investment or investment activity to which this document relates is only available to major institutional investors and will be engaged in only with major institutional investors. In reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act") and interpretations thereof by the U.S. Securities and Exchange Commission ("SEC") in order to conduct business with Institutional Investors based in the U.S., MOFSL has entered into a chaperoning agreement with a U.S. registered broker-dealer, Motilal Oswal Securities International Private Limited. ("MOSIPL"). Any business interaction pursuant to this report will have to be executed within the provisions of this chaperoning agreement.

The Research Analysts contributing to the report may not be registered/qualified as research analyst with FINRA. Such research analyst may not be associated persons of the U.S. registered broker-dealer, MOSIPL, and therefore, may not be subject to NASD rule 2711 and NYSE Rule 472 restrictions on communication with a subject company, public appearances and trading securities held by a research analyst account.

For Singapore

In Singapore, this report is being distributed by Motilal Oswal Capital Markets (Singapore) Pte. Ltd. ("MOCMSPL") (UEN 201129401Z), which is a holder of a capital markets services license and an exempt financial adviser in Singapore. This report is distributed solely to persons who (a) qualify as "institutional investors" as defined in section 4A(1)(c) of the Securities and Futures Act of Singapore ("SFA") or (b) are considered "accredited investors" as defined in section 2(1) of the Financial Advisers Regulations of Singapore read with section 4A(1)(a) of the SFA. Accordingly, if a recipient is neither an "institutional investor" nor an "accredited investor", they must immediately discontinue any use of this Report and inform MOCMSPL.

In respect of any matter arising from or in connection with the research you could contact the following representatives of MOCMSPL. In case of grievances for any of the services rendered by MOCMSPL write to grievances@motilaloswal.com.

Nainesh Rajani

Email: nainesh.rajani@motilaloswal.com

Contact: (+65) 8328 0276

Specific Disclosures

- 1 MOFSL, Research Analyst and/or his relatives does not have financial interest in the subject company, as they do not have equity holdings in the subject company.
- 2 MOFSL, Research Analyst and/or his relatives do not have actual/beneficial ownership of 1% or more securities in the subject company
- 3 MOFSL, Research Analyst and/or his relatives have not received compensation/other benefits from the subject company in the past 12 months
- 4 MOFSL, Research Analyst and/or his relatives do not have material conflict of interest in the subject company at the time of publication of research report
- 5 Research Analyst has not served as director/officer/employee in the subject company
- 6 MOFSL has not acted as a manager or co-manager of public offering of securities of the subject company in past 12 months
- 7 MOFSL has not received compensation for investment banking/ merchant banking/brokerage services from the subject company in the past 12 months
- 8 MOFSL has not received compensation for other than investment banking/merchant banking/brokerage services from the subject company in the past 12 months
- 9 MOFSL has not received any compensation or other benefits from third party in connection with the research report
- 10 MOFSL has not engaged in market making activity for the subject company

The associates of MOFSL may have:

- financial interest in the subject company
- actual/beneficial ownership of 1% or more securities in the subject company at the end of the month immediately preceding the date of publication of the Research Report or date of the public appearance.
- received compensation/other benefits from the subject company in the past 12 months
- any other potential conflict of interests with respect to any recommendation and other related information and opinions; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.
- acted as a manager or co-manager of public offering of securities of the subject company in past 12 months
- be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies)

- received compensation from the subject company in the past 12 months for investment banking / merchant banking / brokerage services or from other than said services.
 - Served subject company as its clients during twelve months preceding the date of distribution of the research report.
- The associates of MOFSL has not received any compensation or other benefits from third party in connection with the research report
- Above disclosures include beneficial holdings lying in demat account of MOFSL which are opened for proprietary investments only. While calculating beneficial holdings, It does not consider demat accounts which are opened in name of MOFSL for other purposes (i.e holding client securities, collaterals, error trades etc.). MOFSL also earns DP income from clients which are not considered in above disclosures.

Analyst Certification

The views expressed in this research report accurately reflect the personal views of the analyst(s) about the subject securities or issues, and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report.

Terms & Conditions:

This report has been prepared by MOFSL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of MOFSL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The intent of this report is not recommendatory in nature. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and does not constitute an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. MOFSL will not treat recipients as customers by virtue of their receiving this report.

Disclaimer:

The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent. This report and information herein is solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. Certain transactions -including those involving futures, options, another derivative products as well as non-investment grade securities - involve substantial risk and are not suitable for all investors. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information and opinions contained in this document. The Disclosures of Interest Statement incorporated in this document is provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. This information is subject to change without any prior notice. The Company reserves the right to make modifications and alterations to this statement as may be required from time to time without any prior approval. MOFSL, its associates, their directors and the employees may from time to time, effect or have effected an own account transaction in, or deal as principal or agent in or for the securities mentioned in this document. They may perform or seek to perform investment banking or other services for, or solicit investment banking or other business from, any company referred to in this report. Each of these entities functions as a separate, distinct and independent of each other. The recipient should take this into account before interpreting the document. This report has been prepared on the basis of information that is already available in publicly accessible media or developed through analysis of MOFSL. The views expressed are those of the analyst, and the Company may or may not subscribe to all the views expressed therein. This document is being supplied to you solely for your information and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published, copied, in whole or in part, for any purpose. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction. Neither the Firm, not its directors, employees, agents or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information. The person accessing this information specifically agrees to exempt MOFSL or any of its affiliates or employees from, any and all responsibility/liability arising from such misuse and agrees not to hold MOFSL or any of its affiliates or employees responsible for any such misuse and further agrees to hold MOFSL or any of its affiliates or employees free and harmless from all losses, costs, damages, expenses that may be suffered by the person accessing this information due to any errors and delays.

This report is meant for the clients of Motilal Oswal only.

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Registered Office Address: Motilal Oswal Tower, Rahimtullah Sayani Road, Opposite Parel ST Depot, Prabhadevi, Mumbai-400025; Tel No.: 022 - 71934200 / 71934263; www.motilaloswal.com.

Correspondence Address: Palm Spring Centre, 2nd Floor, Palm Court Complex, New Link Road, Malad (West), Mumbai- 400 064. Tel No: 022 71881000. Details of Compliance Officer: Neeraj Agarwal,

Email Id: na@motilaloswal.com, Contact No.:022-40548085.

Grievance Redressal Cell:

Contact Person	Contact No.	Email ID
Ms. Hemangi Date	022 40548000 / 022 67490600	query@motilaloswal.com
Ms. Kumud Upadhyay	022 40548082	servicehead@motilaloswal.com
Mr. Ajay Menon	022 40548083	am@motilaloswal.com

Registration details of group entities: Motilal Oswal Financial Services Ltd. (MOFSL): INZ000158836 (BSE/NSE/MCX/NCDEX); CDSL and NSDL: IN-DP-16-2015; Research Analyst: INH000000412. AMFI: ARN : 146822. IRDA Corporate Agent – CA0579. Motilal Oswal Financial Services Ltd. is a distributor of Mutual Funds, PMS, Fixed Deposit, Insurance, Bond, NCDs and IPO products.

Customer having any query/feedback/ clarification may write to query@motilaloswal.com. In case of grievances for any of the services rendered by Motilal Oswal Financial Services Limited (MOFSL) write to grievances@motilaloswal.com, for DP to dpgrievances@motilaloswal.com.